Renal dosimetry in peptide radionuclide receptor therapy.
Abstract This study evaluates the predictive value of absorbed dose, biological effective dose, and time-dose-fractionation factors for use in patients receiving peptide radionuclide receptor therapy treatments by reanalyzing data in two different patient populations that have been reported in the literature. The analysis suggested that the alternative time-dose-fractionation model is as good and, in some cases, may be better in predicting kidney toxicity in these two patient populations than biological effective dose. This study suggests that future investigations proceed with more critical evaluation of different dosimetric quantities that may be more clinically useful in providing optimal patient treatment prescriptions for peptide radionuclide receptor therapy, rather than rely solely on a single methodology derived from experience with external-beam therapy.
Siegel
Jeffry A
JA
Nuclear Physics Enterprises, Marlton, New Jersey, USA.
Stabin
Michael G
MG
Sharkey
Robert M
RM
D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D007668:Kidney / Q000528:radiation effects*; D008962:Models, Theoretical; D011237:Predictive Value of Tests; D011832:Radiation Injuries / Q000517:prevention & control; D011868:Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D011874:Radiometry / Q000379:methods; D019275:Radiopharmaceuticals / Q000009:adverse effects* / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D018000:Receptors, Peptide / Q000627:therapeutic use*; D012189:Retrospective Studies
D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide